Targeting ceramide synthesis to reverse insulin resistance.
Schmitz-Peiffer
Carsten
C
Garvan Institute of Medical Research, Sydney, Australia. c.schmitz-peiffer@garvan.org.au
D000273:Adipose Tissue / Q000033:anatomy & histology; D002518:Ceramides / Q000096:biosynthesis / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D009765:Obesity / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D010171:Palmitoyl Coenzyme A / Q000378:metabolism; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism
D002518:Ceramides; D005229:Fatty Acids, Monounsaturated; D010171:Palmitoyl Coenzyme A; D013108:Sphingomyelin Phosphodiesterase; C001996:thermozymocidin